EichorEICHOR
Location: Florence Synced from ClinicalTrials.gov · August 07, 2026

Clinical studies recruiting near Florence

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

Neurosurgical Outcome Network
Phase N/A · Azienda Ospedaliero Universitaria Careggi · Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta · NCT06724029KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used W
Phase 1/Phase 2 · Azienda Ospedaliera Universitaria Careggi ( Site 0173) · Merck Sharp & Dohme LLC · NCT04165070A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
Phase 3 · Azienda Ospedaliera Universitaria Careggi ( Site 2700) · Merck Sharp & Dohme LLC · NCT06351631Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
Phase 3 · Azienda Ospedaliera Universitaria Careggi · Daiichi Sankyo · NCT07022483Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia
Phase 3 · Azienda Ospedaliera Universitaria Meyer IRCCS · Princess Maxima Center for Pediatric Oncology · NCT05327894A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line
Phase 3 · Merck Sharp & Dohme LLC · NCT06136559Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Phase 3 · Azienda Ospedaliera Universitaria Careggi ( Site 1805) · Merck Sharp & Dohme LLC · NCT06393374A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hem
Phase 3 · AOU Careggi · Regeneron Pharmaceuticals · NCT07154745Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML
Phase 3 · Aou Careggi - Firenze - Sod Ematologia · Gruppo Italiano Malattie EMatologiche dell'Adulto · NCT04168502A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
Phase 3 · Azienda Ospedaliero Universitaria A Meyer (Duplicate) · H. Lundbeck A/S · NCT05897320Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer
Phase 3 · AGO Study Group · NCT05009082Efficacy of a Video-Based Educational Program on Female Urinary Incontinence
NA · Poitiers University Hospital · NCT07105150A Study of Zasocitinib in Adults With Nonsegmental Vitiligo
Phase 2 · Azienda Usl Toscana Centro · Takeda · NCT07108283A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease
Phase 3 · AOU Meyer IRCCS-Site Number : 3800003 · Sanofi · NCT07190196First-In-Human Clinical Study for Treatment of Severe Mitral Valve INsufficiency With Epygon™ TRanscatheter Mitral VAlve
NA · Careggi Hospital Florence Italy Largo Brambilla · Epygon · NCT04775108A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease
Phase 2 · Azienda Ospedaliera Universitaria Careggi · Eli Lilly and Company · NCT07483099Observational Study on Skeletal Ewing's Sarcoma
Phase N/A · A.O. Universitaria Meyer · Italian Sarcoma Group · NCT04845893Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
Phase 3 · Clinical Study Site · Summit Therapeutics · NCT07228832Preoperative vs Postoperative Hypofractionated Radiosurgery for Patients With Large Brain Metastases
NA · AOUC Azienda Ospedaliero-Universitaria Careggi · Istituto Clinico Humanitas · NCT05545007Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormon
Phase N/A · Azienda Ospedaliero Universitaria Careggi · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · NCT06805812A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies
Phase 1/Phase 2 · AOU Careggi - Padiglione 16 - Piano Terra - Ambulatori Oncol · Deciphera Pharmaceuticals, LLC · NCT05957367Endometrial Cancer Lymphadenectomy Trial
NA · Philipps University Marburg · NCT03438474A Prospective Randomised Study of Treatment Selection Based on Epigenetic Markers Versus Standard of Care Treatment Sele
NA · Azienda Ospedaliero Universitaria Careggi Padiglione San Luc · Alimentiv Inc. · NCT07363044A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia
Phase 3 · Universita Degli Studi Di Firenze - Azienda Ospedaliero-Univ · argenx · NCT06544499A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine
Phase 3 · Azienda Ospedaliera Universitaria Careggi, Merz Investigatio · Merz Therapeutics GmbH · NCT07018700A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Dia
Phase 3 · Azienda Ospedaliera Universitaria Careggi · Eli Lilly and Company · NCT07222332A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathie
Phase 3 · Azienda Ospedaliera Universitaria Careggi · Pfizer · NCT05895786Molecular Mechanisms of Disease Relapse After Allogenic Stem Cell Transplantation in MDS Patients
NA · Unità di Ricerca e di Malattie del sangue - Ematologia S. Lu · Gruppo Italiano Malattie EMatologiche dell'Adulto · NCT04587856A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)
Phase 3 · Azienda Ospedaliero Universitaria A Meyer (Duplicate) · Longboard Pharmaceuticals · NCT06660394Understanding the Long-Term Management of Organic Acidemia Patients With CARBAGLU®: A Mixed Methods Approach
Phase N/A · Azienda Ospedaliero Universitaria Meyer · RECORDATI GROUP · NCT04176523
Look up another city
Look up another condition
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.